Immunosuppressant management upon elexacaftor/tezacaftor/ivacaftor initiation in cystic fibrosis patients with prior liver transplant

We read with great interest the report by Tachtatzis et  al. detailing post-liver transplant introduction of elexacaftor/tezacaftor/ivacaftor (ETI) [1]. At our center, the transplant hepatology unit has followed 5 patients, all male, ranging from 22 to 43 years of age, with prior liver transplant (LT) for cystic fibrosis (CF) and recent initiation of ET I (Detailed in Table 1). Median pre-treatment FEV1 was 63 % (33% – 83%). In four cases, immunosuppressive regimen consisted of tacrolimus and in one, a combination of sirolimus and mycophenolate mofetil.

Source: Journal of Cystic Fibrosis - November 24, 2023 Category: Respiratory Medicine Authors: Diana Coman, Catherine Vincent, Genevieve Huard, Denis Marleau, Annick Lavoie, Julian Hercun Source Type: research